Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study

BACKGROUND: High quantities of tumour-infiltrating lymphocytes (TILs) in primary HER2-positive breast cancer are associated with improved prognosis and response to therapy. We aimed to investigate the prognostic role of host antitumour immunity as represented by baseline quantities of TILs in patien...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Lancet Oncol
Main Authors: Luen, Stephen J, Salgado, Roberto, Fox, Stephen, Savas, Peter, Eng-Wong, Jennifer, Clark, Emma, Kiermaier, Astrid, Swain, Sandra M, Baselga, Jose, Michiels, Stefan, Loi, Sherene
Formato: Artigo
Idioma:Inglês
Publicado: 2016
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5477653/
https://ncbi.nlm.nih.gov/pubmed/27964843
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)30631-3
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares